Cytokinetics (NASDAQ:CYTK) Stock: Insider Fady Ibraham Malik Sells 3,500 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Malik sold 3,500 shares of Cytokinetics stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $64.01, for a total transaction of $224,035.00. Following the sale, the executive vice president directly owned 153,902 shares of the company’s stock, valued at approximately $9,851,267.02. This trade represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $61.38, for a total value of $214,830.00.
• On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $68.29, for a total value of $239,015.00.
• On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $75.46, for a total value of $264,110.00.
• On Tuesday, August 18th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $75.82, for a total value of $265,370.00.

Cytokinetics Stock Performance

CYTK opened at $62.86 on Thursday. Cytokinetics, Incorporated has a one year low of $54.30 and a one year high of $88.31. The company has a market cap of $7.82 billion, a P/E ratio of -8.71 and a beta of 0.41. The business’s 50-day simple moving average is $69.38 and its 200-day simple moving average is $73.21.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analysts’ expectations of $17.59 million. Cytokinetics’s revenue for the quarter was down 57.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.12) EPS. As a group, analysts predict that Cytokinetics, Incorporated will post -5.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CYTK. Crossmark Global Holdings Inc. boosted its holdings in shares of Cytokinetics by 3.8% in the third quarter. Crossmark Global Holdings Inc. now owns 9,263 shares of the biopharmaceutical company’s stock valued at $611,000 after acquiring an additional 340 shares during the period. Physician Wealth Advisors Inc. grew its position in shares of Cytokinetics by 810.2% during the third quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 397 shares during the last quarter. Pinnacle Associates Ltd. increased its holdings in shares of Cytokinetics by 6.7% in the 3rd quarter. Pinnacle Associates Ltd. now owns 215,952 shares of the biopharmaceutical company’s stock valued at $14,233,000 after acquiring an additional 13,512 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Cytokinetics by 2.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 13,050 shares of the biopharmaceutical company’s stock valued at $860,000 after acquiring an additional 345 shares during the period. Finally, AMI Asset Management Corp increased its holdings in shares of Cytokinetics by 3.8% in the 3rd quarter. AMI Asset Management Corp now owns 14,800 shares of the biopharmaceutical company’s stock valued at $975,000 after acquiring an additional 539 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CYTK shares. Needham & Company LLC raised their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Citizens Jmp increased their target price on shares of Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and a consensus target price of $105.44.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Cytokinetics, providing continued analyst support for the company’s pipeline and commercial prospects. HC Wainwright rating report
• Positive Sentiment: Cytokinetics scheduled its third-quarter results for November 4, 2026, followed by a management conference call. The report will provide an important update on financial performance, aficamten commercialization and the company’s outlook. Cytokinetics third-quarter results announcement
• Neutral Sentiment: The company granted inducement awards covering 60,465 shares through stock options and 40,084 restricted stock units to 29 new employees. The grants support hiring but could modestly dilute existing shareholders over time. Cytokinetics inducement grants announcement
• Negative Sentiment: BofA Securities reduced its price target to $81 from $85 while maintaining a Neutral rating, signaling more limited near-term conviction even though the target remains above recent trading levels. BofA Securities price-target update
• Negative Sentiment: Wall Street Zen lowered Cytokinetics to a Sell rating, adding to concerns about valuation, execution and the company’s continuing losses. Wall Street Zen downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares for approximately $224,000. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, its bearish signaling value is limited, but it adds to the recent pattern of insider sales. SEC insider transaction filing

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.